SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
GLP-1s
GLP-1s
Commentary
Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud
By
Ari Yampolsky
and
Max Voldman
August 12, 2025
Newsletters
Exclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
By
Emma Hinchliffe
August 7, 2025
Newsletters
Behold, an AI model from OpenAI that’s…open
By
Andrew Nusca
August 6, 2025
Health
Weight-loss drugs should be first step to prevent heart disease, top cardiology group says
By
Michelle Amponsah
and
Bloomberg
June 20, 2025
Lifestyle
Agency warns that weight-loss drugs can decrease effectiveness of birth control pills
By
Beth Greenfield
June 5, 2025
Health
The Ozempic boom could be bad news for restaurants as more than half of GLP-1 users report cutting back on dining out, report finds
By
Sasha Rogelberg
June 4, 2025
Commentary
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By
Wendy Barnes
March 4, 2025
Health
50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage
By
Tom Murphy
and
The Associated Press
February 24, 2025
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By
Bloomberg
,
Madison Muller
,
Ike Swetlitz
and
Naomi Kresge
February 21, 2025
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By
Lindsey Leake
February 11, 2025
Health
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
By
Hallie Steiner
February 4, 2025
Health
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
By
Ryan Hogg
February 4, 2025
Health
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By
Lindsey Leake
February 3, 2025
Health
Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity
By
The Associated Press
,
Kenya Hunter
and
Linley Sanders
January 31, 2025
Health
Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By
Lindsey Leake
January 29, 2025
Most Popular
North America
Farmer says 'we're in a very dire situation' ahead of harvest—with zero soybean orders from China, historically the...
By
Dave Smith
Success
This Stanford computer science professor went to written exams 2 years ago because of AI. He says his students insisted...
By
Nick Lichtenberg
Success
Workday’s CEO says his career took off after he changed his attitude—and Amazon boss Andy Jassy swears by the same...
By
Preston Fore